Accelerate Diagnostics

AXDX

ATLANTA, GA – – (ACCESSWIRE – October 27, 2022) – – Holzer & Holzer, LLC is investigating whether Accelerate Diagnostics, Inc. (“Accelerate Diagnostics” or the “Company”) (NASDAQ: AXDX) complied with federal securities laws.  On October 21, 2022, Accelerate Diagnostics announced that it was required by the FDA to obtain 510(k) clearance for its Accelerate Arc Products, discontinue US marketing and distribution of those products, and revise/remove the Company’s registration and listing of those products as Class I devices.  Following this announcement, the Company’s stock price dropped.

 

If you purchased Accelerate Diagnostics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/accelerate-diagnostics/  to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
 
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.